📊 TYRA Key Takeaways
Is Tyra Biosciences, Inc. (TYRA) a Good Investment?
Tyra Biosciences is a pre-commercial stage biotech company with no reported revenue, burning $95M annually in operating cash flow, and deteriorating losses (down 38.7% YoY). While the balance sheet shows adequate equity and liquidity, the company faces severe execution risk with less than one year of cash runway at current burn rates and absolute dependence on successful drug development and commercialization.
Why Buy Tyra Biosciences, Inc. Stock? TYRA Key Strengths
- Strong balance sheet with $259.2M stockholders equity and minimal debt (0.00x D/E ratio)
- Adequate cash position of $77.4M with exceptional liquidity ratios (14.67x current ratio)
- No near-term debt obligations allowing flexibility for capital deployment
TYRA Stock Risks: Tyra Biosciences, Inc. Investment Risks
- No revenue generation indicates pre-commercial stage with significant development risk
- Operating losses expanding YoY (38.7% deterioration in net income), signaling worsening cash burn
- Cash runway of approximately 9-10 months at current $95.1M annual operating cash burn rate
- Requires successful Phase III trials, regulatory approval, and market adoption to achieve profitability
- Biotech dependency on single or limited drug pipeline with binary success/failure outcomes
Key Metrics to Watch
- Operating cash flow trend and runway extension through capital raises or cost reduction
- Clinical trial progress updates and regulatory milestones for lead drug candidates
- Quarterly cash burn rate and changes in cash reserves
- Patent expirations and competitive pipeline developments in target therapeutic areas
Tyra Biosciences, Inc. (TYRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.67x current ratio provides a solid financial cushion.
TYRA Profit Margin, ROE & Profitability Analysis
TYRA vs Healthcare Sector: How Tyra Biosciences, Inc. Compares
How Tyra Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tyra Biosciences, Inc. Stock Overvalued? TYRA Valuation Analysis 2026
Based on fundamental analysis, Tyra Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tyra Biosciences, Inc. Balance Sheet: TYRA Debt, Cash & Liquidity
TYRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tyra Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.51 indicates the company is currently unprofitable.
TYRA Revenue Growth, EPS Growth & YoY Performance
Tyra Biosciences, Inc. Dividends, Buybacks & Capital Allocation
TYRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tyra Biosciences, Inc. (CIK: 0001863127)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TYRA
What is the AI rating for TYRA?
Tyra Biosciences, Inc. (TYRA) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TYRA's key strengths?
Claude: Strong balance sheet with $259.2M stockholders equity and minimal debt (0.00x D/E ratio). Adequate cash position of $77.4M with exceptional liquidity ratios (14.67x current ratio).
What are the risks of investing in TYRA?
Claude: No revenue generation indicates pre-commercial stage with significant development risk. Operating losses expanding YoY (38.7% deterioration in net income), signaling worsening cash burn.
What is TYRA's revenue and growth?
Tyra Biosciences, Inc. reported revenue of N/A.
Does TYRA pay dividends?
Tyra Biosciences, Inc. does not currently pay dividends.
Where can I find TYRA SEC filings?
Official SEC filings for Tyra Biosciences, Inc. (CIK: 0001863127) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TYRA's EPS?
Tyra Biosciences, Inc. has a diluted EPS of $-2.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TYRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Tyra Biosciences, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TYRA stock overvalued or undervalued?
Valuation metrics for TYRA: ROE of -46.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TYRA stock in 2026?
Our dual AI analysis gives Tyra Biosciences, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TYRA's free cash flow?
Tyra Biosciences, Inc.'s operating cash flow is $-95.1M, with capital expenditures of $141.0K.
How does TYRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -46.3% (avg: 15%), current ratio 14.67 (avg: 2).